The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption

References

• Aires V, Limagne E, Cotte AK, Latruffe N, Ghiringhelli F, Delmas D. 2013. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res. 57(7):1170–1181.
   PubMed Web of Science ®Google Scholar
• Akingbemi BT, Ge R, Rosenfeld CS, Newton LG, Hardy DO, Catterall JF, Lubahn DB, Korach KS, Hardy MP. 2003. Estrogen receptor-gene deficiency enhances androgen biosynthesis in the mouse Leydig cell. Endocrinology. 144(1):84–93.
   PubMed Web of Science ®Google Scholar
• Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha J-F, Nunes T, Wright L, et al. 2009. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 53(S1):S7–S15.
   PubMed Web of Science ®Google Scholar
• Amiot MJ, Romier B, Anh Dao T-M, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, Emond C, Savouret J-F, Seree E, et al. 2013. Optimization of trans-resveratrol bioavailability for human therapy. Biochimie. 95(6):1233–1238.
   PubMed Web of Science ®Google Scholar
• Andreadi C, Britton RG, Patel KR, Brown K. 2014. Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy. 10(3):524–525.
   PubMed Web of Science ®Google Scholar
• Andreani C, Bartolacci C, Wijnant K, Crinelli R, Bianchi M, Magnani M, Hysi A, Iezzi M, Amici A, Marchini C, et al. 2017. Resveratrol fuels HER2 and ER-positive breast cancer behaving as proteasome inhibitor. Aging. 9(2):508–523.
   PubMedGoogle Scholar
• Ashby J. 2000. Validation of in vitro and in vivo methods for assessing endocrine disrupting chemicals. Toxicol Pathol. 28(3):432–437.
   PubMed Web of Science ®Google Scholar
• Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N, Sumpter JP. 1999. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol. 19(1):39–45.
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. 2009. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 486(2):95–102.
   PubMed Web of Science ®Google Scholar
• Banaszewska B, Wrotyńska-Barczyńska J, Spaczynski RZ, Pawelczyk L, Duleba AJ. 2016. Effects of resveratrol on polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 101(11):4322–4328.
   PubMed Web of Science ®Google Scholar
• Banu SK, Stanley JA, Sivakumar KK, Arosh JA, Burghardt RC. 2016. Resveratrol protects the ovary against chromium-toxicity by enhancing endogenous antioxidant enzymes and inhibiting metabolic clearance of estradiol. Toxicol Appl Pharmacol. 303:65–78.
   PubMed Web of Science ®Google Scholar
• Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ. 2000. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 66(9):769–777.
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444(7117):337–342.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5(6):493–506.
   PubMed Web of Science ®Google Scholar
• Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. 2017. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 1:1–9.
   PubMed Web of Science ®Google Scholar
• Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, Bertelli A. 1998. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res. 24(1):51–55.
   PubMedGoogle Scholar
• Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61(20):7456–7463.
   PubMed Web of Science ®Google Scholar
• Bhat KP, Pezzuto JM. 2001. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 61:6137–6144.
   PubMed Web of Science ®Google Scholar
• Bhat KP, Pezzuto JM. 2002. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci. 957(1):210–229.
   PubMed Web of Science ®Google Scholar
• Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 16(6):1246–1252.
   PubMed Web of Science ®Google Scholar
• Borgert CJ, LaKind JS, Witorsch RJ. 2003. A critical review of methods for comparing estrogenic activity of endogenous and exogenous chemicals in human milk and infant formula. Environ Health Perspect. 111(8):1020–1036.
   PubMed Web of Science ®Google Scholar
• Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. 2000. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 141(10):3657–3667.
   PubMed Web of Science ®Google Scholar
• Bresciani L, Calani L, Bocchi L, Delucchi F, Savi M, Ray S, Brighenti F, Stilli D, Del Rio D. 2014. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr Metab Cardiovasc Dis. 24(4):408–415.
   PubMed Web of Science ®Google Scholar
• Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, et al. 2010. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70(22):9003–9011.
   PubMed Web of Science ®Google Scholar
• Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. 2002. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 50(11):3337–3340.
   PubMed Web of Science ®Google Scholar
• Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 429(2):273–282.
   PubMed Web of Science ®Google Scholar
• Castiglione F, Taddei A, Rossi Degl'Innocenti D, Buccoliero AM, Bechi P, Garbini F, Chiara FG, Moncini D, Cavallina G, Marascio L, et al. 2008. Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol. 17(4):231–236.
   PubMedGoogle Scholar
• Cavalieri EL, Rogan EG. 2011. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol. 125(3–5):169–180.
   PubMed Web of Science ®Google Scholar
• Cavalieri E, Saeed M, Zahid M, Cassada D, Snow D, Miljkovic M, Rogan E. 2012. Mechanism of DNA depurination by carcinogens in relation to cancer initiation. IUBMB Life. 64(2):169–179.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Levenson AS, Biswas PK. 2013. Structural insights into resveratrol’s antagonist and partial agonist actions on estrogen receptor alpha. BMC Struct Biol. 13(1):27–11.
   PubMed Web of Science ®Google Scholar
• Chen YC, Nagpal ML, Stocco DM, Lin T. 2007. Effects of genistein, resveratrol, and quercetin on steroidogenesis and proliferation of MA-10 mouse Leydig tumor cells. J Endocrinol. 192(3):527–537.
   PubMed Web of Science ®Google Scholar
• Chottanapund S, Van Duursen MBM, Navasumrit P, Hunsonti P, Timtavorn S, Ruchirawat M, Van den Berg M. 2014. Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts. Toxicol in Vitro. 28(7):1215–1221.
   PubMed Web of Science ®Google Scholar
• Chow H-HS, Garland LL, Heckman-Stoddard BM, Hsu C-H, Butler VD, Cordova CA, Chew WM, Cornelison TL. 2014. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med. 12(1):223–227.
   PubMed Web of Science ®Google Scholar
• Chow H-HS, Garland LL, Hsu C-H, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 3(9):1168–1175.
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim MY, Guengerich FP. 1999. Resveratrol is a selective human cytochrome P450 1A1 Inhibitor. Biochem Biophys Res Commun. 262(1):20–24.
   PubMed Web of Science ®Google Scholar
• Clode SA. 2006. Assessment of in vivo assays for endocrine disruption. Best Pract Res Clin Endocrinol Metab. 20(1):35–43.
   PubMed Web of Science ®Google Scholar
• Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. 2004. Resveratrol-associated renal toxicity. Toxicol Sci. 82(2):614–619.
   PubMed Web of Science ®Google Scholar
• De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SAW, Andò S. 2011. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 25(10):3695–3707.
   PubMed Web of Science ®Google Scholar
• Deng JY, Hsieh PS, Huang JP, Lu LS, Hung LM. 2008. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes. 57(7):1814–1823.
   PubMed Web of Science ®Google Scholar
• Diel P, Smolnikar K, Michna H. 1999. In vitro test systems for the evaluation of the estrogenic activity of natural products. Planta Med. 65(3):197–203.
   PubMed Web of Science ®Google Scholar
• Duffy MJ. 2006. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci. 43(4):325–347.
   PubMed Web of Science ®Google Scholar
• Edwards JA, Beck M, Riegger C, Bausch J. 2011. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida®. Ann NY Acad Sci. 1215(1):131–137.
   PubMed Web of Science ®Google Scholar
• EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2016. Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. 14(1), article number 4368, 30 pp.
   Google Scholar
• Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. 2007. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol. 50(1):83–93.
   PubMed Web of Science ®Google Scholar
• el-Mowafy AM, Abou-Zeid LA, Edafiogho I. 2002. Recognition of resveratrol by the human estrogen receptor-alpha: a molecular modeling approach to understand its biological actions. Med Principles Pract. 11(2):86–92.
   PubMed Web of Science ®Google Scholar
• Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR, Chen S. 2001. Suppression of aromatase (estrogen synthetase) by red wine phytochemicals. Breast Cancer Res Treat. 67(2):133–146.
   PubMed Web of Science ®Google Scholar
• Eng ET, Williams D, Mandava U, Kirma N, Tekmal RR, Chen S. 2002. Anti-aromatase chemicals in red wine. Ann N Y Acad Sci. 963(1):239–246.
   PubMed Web of Science ®Google Scholar
• Evans RM. 1988. The steroid and thyroid hormone receptor superfamily. Science. 240(4854):889–895.
   PubMed Web of Science ®Google Scholar
• Freyberger A, Hartmann E, Hildebrand H, Krotlinger F. 2001. Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. Arch Toxicol. 74(11):709–715.
   PubMed Web of Science ®Google Scholar
• Furimsky AM, Green CE, Sharp LEH, Catz P, Adjei AA, Parman T, Kapetanovic IM, Weinshilboum RM, Iyer LV. 2008. Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metab Dispos. 36(1):129–136.
   PubMed Web of Science ®Google Scholar
• Garvin S, Öllinger K, Dabrosin C. 2006. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231(1):113–122.
   PubMed Web of Science ®Google Scholar
• Gehm BD, Levenson AS, Liu H, Lee E-J, Amundsen BM, Cushman M, Jordan VC, Jameson JL. 2004. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol. 88(3):223–234.
   PubMed Web of Science ®Google Scholar
• Gehm BD, McAndrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 94(25):14138–14143.
   PubMed Web of Science ®Google Scholar
• Goldberg DM, Hahn SE, Parkes JG. 1995. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta. 237(1–2):155–187.
   PubMed Web of Science ®Google Scholar
• Goldberg DM, Yan J, Soleas GJ. 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 36(1):79–87.
   PubMed Web of Science ®Google Scholar
• Golden R, Gandy J, Vollmer G. 2005. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol. 35(5):435–458.
   PubMed Web of Science ®Google Scholar
• Gu J, Wang C, Fan H, Ding H, Xie X, Xu Y, et al. 2006. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol. 47:711–721.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Chun YJ, Kim D, Gillam EMJ, Shimada T. 2003. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res Fund Mol Mech Mutagen. 523-524:173–182.
   PubMed Web of Science ®Google Scholar
• Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, et al. 2007. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 87(3):905–931.
   PubMed Web of Science ®Google Scholar
• Henry LA, Witt DM. 2002. Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats. Horm Behav. 41(2):220–228.
   PubMed Web of Science ®Google Scholar
• Henry LA, Witt DM. 2006. Effects of neonatal resveratrol exposure on adult male and female reproductive physiology and behavior. Dev Neurosci. 28(3):186–195.
   PubMed Web of Science ®Google Scholar
• Hewitt SC, Korach KS. 2018. Estrogen receptors: new directions in the new millennium. Endocr Rev. 39(5):664–675.
   PubMed Web of Science ®Google Scholar
• Horgan XJ, Tatum H, Brannan E, Paull DH, Rhodes LV. 2019. Resveratrol analogues surprisingly effective against triple-negative breast cancer, independent of ERα. Oncol Rep. 41(6):3517–3526.
   PubMed Web of Science ®Google Scholar
• Hoshino J, Park E-J, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y, Cushman M. 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 53(13):5033–5043.
   PubMed Web of Science ®Google Scholar
• Houk CP, Pearson EJ, Martinelle N, Donahoe PK, Teixeira J. 2004. Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology. 145(3):1269–1275.
   PubMed Web of Science ®Google Scholar
• Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang L-L, et al. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 425(6954):191–196.
   PubMed Web of Science ®Google Scholar
• Hsieh T, Wu JM. 1999. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res. 249(1):109–115.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275(5297):218–220.
   PubMed Web of Science ®Google Scholar
• Jassam N, Bell SM, Speirs V, Quirke P. 2005. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol. Rep. 14(1):17–21.
   PubMed Web of Science ®Google Scholar
• Johnson WD, Morrissey RL, Usborne AL, Kapetanovic I, Crowell JA, Muzzio M, McCormick DL. 2011. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol. 49(12):3319–3327.
   PubMed Web of Science ®Google Scholar
• Juan ME, Vinardell MP, Planas JM. 2002. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr. 132(2):257–260.
   PubMed Web of Science ®Google Scholar
• Kang NH, Hwang KA, Kim TH, Hyun SH, Jeung EB, Choi KC. 2012. Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression. Mol Med Rep. 6(1):151–156.
   PubMed Web of Science ®Google Scholar
• Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. 2011. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 68(3):593–601.
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G. 2002. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 94:606–616.
   PubMed Web of Science ®Google Scholar
• Kjaer TN, Ornstrup MJ, Poulsen MM, Jørgensen JOL, Hougaard DM, Cohen AS, Neghabat S, Richelsen B, Pedersen SB. 2015. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. Prostate. 75(12):1255–1263.
   PubMed Web of Science ®Google Scholar
• Kjaer TN, Ornstrup MJ, Poulsen MM, Stødkilde-Jørgensen H, Jessen N, Jørgensen JOL, Richelsen B, Pedersen SB. 2017. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 102(5):1642–1651.
   PubMed Web of Science ®Google Scholar
• Kleinstreuer NC, Ceger PC, Allen DG, Strickland J, Chang X, Hamm JT, Casey WM. 2016. A curated database of rodent uterotrophic bioactivity. Environ Health Perspect. 124(5):556–562.
   PubMed Web of Science ®Google Scholar
• Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao L, Brey DM, Keynton RS. 2005. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem. 280(9):7460–7468.
   PubMed Web of Science ®Google Scholar
• Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, Jungbauer A. 2003. Estrogenic activity in white and red wine extracts. J Agric Food Chem. 51(7):1850–1857.
   PubMed Web of Science ®Google Scholar
• Klinge CM, Wickramasinghe NS, Ivanova MM, Dougherty SM. 2008. Resveratrol stimulates nitric oxide production by increasing estrogen receptor α-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J. 22(7):2185–2197.
   PubMed Web of Science ®Google Scholar
• Klotz DM, Beckman BS, Hill SM, McLachlan JA, Walters MR, Arnold SF. 1996. Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays. Environ Health Perspect. 104(10):1084–1089.
   PubMed Web of Science ®Google Scholar
• Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R. 1996. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am. J. Pathol. 148(3):969–976.
   PubMed Web of Science ®Google Scholar
• Korhammer S, Reniero F, Mattivi F. 1995. An oligostilbene from vitis roots. Phytochemistry. 38(6):1501–1504.
   Web of Science ®Google Scholar
• Kulkarni SS, Canto C. 2015. The molecular targets of resveratrol. Biochim Biophys Acta. 1852(6):1114–1123.
   PubMed Web of Science ®Google Scholar
• Langcake P, Pryce RJ. 1976. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol. 9(1):77–86.
   Google Scholar
• Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE, Jameson JL, Jordan VC. III,. 2003. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ERα. Int J Cancer. 104(5):587–596.
   PubMed Web of Science ®Google Scholar
• Levi F, Pasche C, Lucchini F, Ghidoni R, Ferraroni M, La VC. 2005. Resveratrol and breast cancer risk. Eur J Cancer Prev. 14(2):139–142.
   PubMed Web of Science ®Google Scholar
• Li PS. 1991. In vitro effects of estradiol, diethylstilbestrol and tamoxifen on testosterone production by purified pig Leydig cells. Chin J Physiol. 34(3):287–301.
   PubMedGoogle Scholar
• Li L, Chen X, Zhu Q, Chen D, Guo J, Yao W, Dong Y, Wei J, Lian Q, Ge R-S, et al. 2014. Disrupting androgen production of Leydig cells by resveratrol via direct inhibition of human and rat 3β-hydroxysteroid dehydrogenase. Toxicol Lett. 226(1):14–19.
   PubMed Web of Science ®Google Scholar
• Lin H-Y, Lansing L, Merillon J-M, Davis FB, Tang H-Y, Shih A, Vitrac X, Krisa S, Keating T, Cao HJ, et al. 2006. Integrin αVb3 contains a receptor site for resveratrol. FASEB J. 20(10):1742–1744.
   PubMed Web of Science ®Google Scholar
• Lu R, Serrero G. 1999. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 179(3):297–304.
   PubMed Web of Science ®Google Scholar
• Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG. 2008. Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res (Phila). 1(2):135–145.
   PubMed Web of Science ®Google Scholar
• Maia H, Jr., Haddad C, Pinheiro N, Casoy J. 2012. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 4:543–549.
   PubMedGoogle Scholar
• Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. 1995. The nuclear receptor superfamily: the second decade. Cell. 83(6):835–839.
   PubMed Web of Science ®Google Scholar
• Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 302(1):369–373.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. 1999. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340(23):1801–1811.
   PubMed Web of Science ®Google Scholar
• Mgbonyebi OP, Russo J, Russo IH. 1998. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol. 12:865–869.
   PubMed Web of Science ®Google Scholar
• Miksits M, Wlcek K, Svoboda M, Thalhammer T, Ellinger I, Stefanzl G, Falany CN, Szekeres T, Jaeger W. 2010. Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism. Cancer Lett. 289(2):237–245.
   PubMed Web of Science ®Google Scholar
• Mikulski D, Molski M. 2010. Quantitative structure-antioxidant activity relationship of trans-resveratrol oligomers, trans-4,4´-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-4´-O-β-D-glucopyranoside. Eur J Med Chem. 45(6):2366–2380.
   PubMed Web of Science ®Google Scholar
• Mizutani K, Ikeda K, Kawai Y, Yamori Y. 1998. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun. 253(3):859–863.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K, Tsubura A. 2001. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J Cancer Res Clin Oncol. 127(4):258–264.
   PubMed Web of Science ®Google Scholar
• Nikaido Y, Danbara N, Tsujita-Kyutoku M, Yuri T, Uehara N, Tsubura A. 2005. Effects of prepubertal exposure to xenoestrogen on development of estrogen target organs in female CD-1 mice. In Vivo. 19:487–494.
   PubMed Web of Science ®Google Scholar
• Nikaido Y, Yoshizawa K, Danbara N, Tsujita-Kyutoku M, Yuri T, Uehara N, Tsubura A. 2004. Effects of maternal xenoestrogen exposure on development of the reproductive tract and mammary gland in female CD-1 mouse offspring. Reprod Toxicol. 18(6):803–811.
   PubMed Web of Science ®Google Scholar
• Ornstrup MJ, Harsløf T, Kjaer TN, Langdahl BL, Pedersen SB. 2014. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 99(12):4720–4729.
   PubMed Web of Science ®Google Scholar
• Ornstrup MJ, Kjaer TN, Harsløf T, Stødkilde-Jørgensen H, Hougaard DM, Cohen A, Pedersen SB, Langdahl BL. 2015. Adipose tissue, estradiol levels, and bone health in obese men with metabolic syndrome. Eur J Endocrinol. 172(2):205–216.
   PubMed Web of Science ®Google Scholar
• Ortega I, Duleba AJ. 2015. Ovarian actions of resveratrol. Ann NY Acad Sci. 1348(1):86–96.
   PubMed Web of Science ®Google Scholar
• Oskarsson A, Spatafora C, Tringali C, Andersson AO. 2014. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs. Prostate. 74(8):839–851.
   PubMed Web of Science ®Google Scholar
• Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. 1995. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 235(2):207–219.
   PubMed Web of Science ®Google Scholar
• Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. 1996. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta. 246(1–2):163–182.
   PubMed Web of Science ®Google Scholar
• Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, et al. 2010. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 285(11):8340–8351.
   PubMed Web of Science ®Google Scholar
• Park EJ, Pezzuto JM. 2015. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 1852(6):1071–1113.
   PubMed Web of Science ®Google Scholar
• Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP, et al. 2013. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med. 5(205):205ra133–205ra133.
   PubMed Web of Science ®Google Scholar
• Patel KR, Brown VA, Jones DJL, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al. 2010. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70(19):7392–7399.
   PubMed Web of Science ®Google Scholar
• Pezzuto JM. 2011. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann N Y Acad Sci. 1215(1):123–130.
   PubMed Web of Science ®Google Scholar
• Pezzuto JM. 2019. Resveratrol: twenty years of growth, development and controversy. Biomol Ther (Seoul). 27(1):1–14.
   PubMed Web of Science ®Google Scholar
• Poschner S, Maier-Salamon A, Zehl M, Wackerlig J, Dobusch D, Meshcheryakova A, et al. 2018. Resveratrol inhibits key steps of steroid metabolism in a human estrogen-receptor positive breast cancer model: impact on cellular proliferation. Front Pharmacol. 9:1–16.
   PubMed Web of Science ®Google Scholar
• Pozo-Guisado E, Lorenzo-Benayas MJ, Fernández-Salguero PM. 2004. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor α-dependent mechanism: relevance in cell proliferation. Int J Cancer. 109(2):167–173.
   PubMed Web of Science ®Google Scholar
• Ramirez I. 1981. Estradiol-induced changes in lipoprotein lipase, eating, and body weight in rats. Am J Physiol. 240(5):E533–E538.
   PubMed Web of Science ®Google Scholar
• Robb EL, Stuart JA. 2011. Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase. Free Radic Biol Med. 50:821–831.
   PubMed Web of Science ®Google Scholar
• Romero-Pérez AI, Ibern-Gómez M, Lamuela-Raventós RM, Torre-Boronat MC. 1999. Piceid, the major resveratrol derivative in grape juices. J Agric Food Chem. 47(4):1533–1536.
   PubMed Web of Science ®Google Scholar
• Ruotolo R, Calani L, Fietta E, Brighenti F, Crozier A, Meda C, Maggi A, Ottonello S, Del Rio D. 2013. Anti-estrogenic activity of a human resveratrol metabolite. Nutr Metab Cardiovasc Dis. 23(11):1086–1092.
   PubMed Web of Science ®Google Scholar
• Saez-Lopez C, Brianso-Llort L, Torres-Torronteras J, Simo R, Hammond GL, Selva DM. 2017. Resveratrol increases hepatic SHBG expression through human constitutive androstane receptor: a new contribution to the French paradox. Sci Rep. 7(1):1–14.
   PubMed Web of Science ®Google Scholar
• Saiko P, Szakmary A, Jaeger W, Szekeres T. 2008. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 658(1–2):68–94.
   PubMed Web of Science ®Google Scholar
• Saleh MC, Connell BJ, Saleh TM. 2010. Resveratrol preconditioning induces cellular stress proteins and is mediated via NMDA and estrogen receptors. Neuroscience. 166(2):445–454.
   PubMed Web of Science ®Google Scholar
• Saleh MC, Connell BJ, Saleh TM. 2013. Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ERα ERβ. Neurosci Lett. 548:217–221.
   PubMed Web of Science ®Google Scholar
• Sato M, Pei RJ, Yuri T, Danbara N, Nakane Y, Tsubura A. 2003. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague—Dawley rats. Cancer Lett. 202(2):137–145.
   PubMed Web of Science ®Google Scholar
• Shanle EK, Xu W. 2011. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol. 24(1):6–19.
   PubMed Web of Science ®Google Scholar
• Sharpe RM. 2003. The ‘oestrogen hypothesis’- where do we stand now? Int J Androl. 26(1):2–15.
   PubMedGoogle Scholar
• Shufelt C, Merz CNB, Yang Y, Kirschner J, Polk D, Stanczyk F, Paul-Labrador M, Braunstein GD. 2012. Red versus white wine as a nutritional aromatase inhibitor in premenopausal women: a pilot study. J Womens Health (Larchmt). 21(3):281–284.
   PubMed Web of Science ®Google Scholar
• Siemann EH, Creasy LL. 1992. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic. 43:49–52.
   Web of Science ®Google Scholar
• Singh CK, Ndiaye MA, Ahmad N. 2015. Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta. 1852(6):1178–1185.
   PubMed Web of Science ®Google Scholar
• Stahl S, Chun TY, Gray WG. 1998. Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Toxicol Appl Pharmacol. 152(1):41–48.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 273(34):21875–21882.
   PubMed Web of Science ®Google Scholar
• Supornsilchai V, Svechnikov K, Seidlova-Wuttke D, Wuttke W, Söder O. 2005. Phytoestrogen resveratrol suppresses steroidogenesis by rat adrenocortical cells by Inhibiting cytochrome P450 c21-hydroxylase. Horm Res Paediatr. 64(6):280–286.
   Web of Science ®Google Scholar
• Svechnikov K, Spatafora C, Svechnikova I, Tringali C, Söder O. 2009. Effects of resveratrol analogs on steroidogenesis and mitochondrial function in rat Leydig cells in vitro. J Appl Toxicol. 29(8):673–680.
   PubMed Web of Science ®Google Scholar
• Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W. 2011. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci. 1215(1):89–95.
   PubMed Web of Science ®Google Scholar
• Tagawa N, Kubota S, Kato I, Kobayashi Y. 2013. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes. J Endocrinol. 218(3):311–320.
   PubMed Web of Science ®Google Scholar
• Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD. 1999. Is resveratrol an estrogen agonist in growing rats? Endocrinology. 140(1):50–54.
   PubMed Web of Science ®Google Scholar
• van Duursen M. 2017. Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women’s health. Toxicol Res (Camb). 6(6):772–794.
   PubMed Web of Science ®Google Scholar
• Vang O. 2013. What is new for resveratrol? Is a new set of recommendations necessary? Ann NY Acad Sci. 1290(1):1–11.
   PubMed Web of Science ®Google Scholar
• Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM, Pedraza V. 1995. The E-screen assay: a comparison of different MCF7 cell stocks. Environ Health Perspect. 103(9):844–850.
   PubMed Web of Science ®Google Scholar
• Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, Marchelli R. 2005. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 49(5):495–504.
   PubMed Web of Science ®Google Scholar
• Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J, Mérillon J-M. 2003. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72(20):2219–2233.
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 32(12):1377–1382.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lee KW, Chan FL, Chen S, Leung LK. 2006. The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol Sci. 92(1):71–77.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Z, Yang S, Yin T, Zhang Y, Qin Y, Weinreb RN, Sun X. 2017. Tissue distribution of trans-resveratrol and its metabolites after oral administration in human eyes. J Ophthalmol. 2017:1–12.
   Web of Science ®Google Scholar
• Weiskirchen S, Weiskirchen R. 2016. Resveratrol: how much wine do you have to drink to stay healthy? Adv Nutr. 7(4):706–718.
   PubMed Web of Science ®Google Scholar
• Whitten PL, Patisaul HB. 2001. Cross-species and interassay comparisons of phytoestrogen action. Environ Health Perspect. 109 (Suppl 1):5–20.
   PubMed Web of Science ®Google Scholar
• Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. 2009. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 47(9):2170–2182.
   PubMed Web of Science ®Google Scholar
• Wong DH, Villanueva JA, Cress AB, Duleba AJ. 2010. Effects of resveratrol on proliferation and apoptosis in rat ovarian theca-interstitial cells. Mol Hum Reprod. 16(4):251–259.
   PubMed Web of Science ®Google Scholar
• Yager JD. 2015. Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention–a review. Steroids. 99:56–60.
   PubMed Web of Science ®Google Scholar
• Yeo SCM, Ho PC, Lin HS. 2013. Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res. 57(6):1015–1025.
   PubMed Web of Science ®Google Scholar
• Yu HP, Hsu JC, Hwang TL, Yen CH, Lau YT. 2008. Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock. 30(3):324–328.
   PubMed Web of Science ®Google Scholar
• Yu HP, Hwang TL, Hsieh PW, Lau YT. 2011. Role of estrogen receptor-dependent upregulation of P38 MAPK/heme oxygenase 1 in resveratrol-mediated attenuation of intestinal injury after trauma-hemorrhage. Shock. 35(5):517–523.
   PubMed Web of Science ®Google Scholar
• Yurdagul A, Kleinedler JJ, McInnis MC, Khandelwal AR, Spence AL, Orr AW, Dugas TR. 2014. Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway. Am J Physiol Heart Circ Physiol. 306(6):H797–H806.
   PubMed Web of Science ®Google Scholar
• Zahid M, Gaikwad NW, Ali MF, Lu F, Saeed M, Yang L, Rogan EG, Cavalieri EL. 2008. Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic Biol Med. 45(2):136–145.
   PubMed Web of Science ®Google Scholar
• Zahid M, Gaikwad NW, Rogan EG, Cavalieri EL. 2007. Inhibition of depurinating estrogen–DNA adduct formation by natural compounds. Chem Res Toxicol. 20(12):1947–1953.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY. 2004. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer. 91(1):178–185.
   PubMed Web of Science ®Google Scholar
• Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh T-c, Wu JM. 2000. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sc. 68(2):153–163.
   PubMed Web of Science ®Google Scholar